Centogene N.V.
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA … Read more
Centogene N.V. (CNTGF) - Net Assets
Latest net assets as of December 2023: $-25.28 Million USD
Based on the latest financial reports, Centogene N.V. (CNTGF) has net assets worth $-25.28 Million USD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($77.16 Million) and total liabilities ($102.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-25.28 Million |
| % of Total Assets | -32.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 177.22 |
Centogene N.V. - Net Assets Trend (2020–2023)
This chart illustrates how Centogene N.V.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Centogene N.V. (2020–2023)
The table below shows the annual net assets of Centogene N.V. from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-25.28 Million | -441.14% |
| 2022-12-31 | $7.41 Million | -72.81% |
| 2021-12-31 | $27.26 Million | -58.02% |
| 2020-12-31 | $64.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Centogene N.V.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11332900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $151.79 Million | % |
| Total Equity | $-25.28 Million | 100.00% |
Centogene N.V. Competitors by Market Cap
The table below lists competitors of Centogene N.V. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IPSEN (I7G.SG)
STU:I7G
|
$1.47 Million |
|
5AP
STU:5AP
|
$1.47 Million |
|
3M Co.
LSE:0QNY
|
$1.47 Million |
|
Tivic Health Systems Inc
NASDAQ:TIVC
|
$1.47 Million |
|
Patriot Gold Corp
PINK:PGOL
|
$1.47 Million |
|
LIQUID META CAPITAL HLDGS
F:N5F
|
$1.47 Million |
|
ENZON PHARM (EZ1.SG)
STU:EZ1
|
$1.47 Million |
|
HANOVER INSURANCE
BE:AF4
|
$1.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Centogene N.V.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 7,411,000 to -25,282,000, a change of -32,693,000 (-441.1%).
- Net loss of 35,532,000 reduced equity.
- Other factors increased equity by 2,839,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-35.53 Million | -140.54% |
| Other Changes | $2.84 Million | +11.23% |
| Total Change | $- | -441.14% |
Book Value vs Market Value Analysis
This analysis compares Centogene N.V.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $2.93 | $0.12 | x |
| 2021-12-31 | $1.20 | $0.12 | x |
| 2022-12-31 | $0.27 | $0.12 | x |
| 2023-12-31 | $-0.87 | $0.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Centogene N.V. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -73.21%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-158.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -33.91% | -57.18% | 0.26x | 2.31x | $-28.47 Million |
| 2021 | -170.87% | -109.50% | 0.46x | 3.37x | $-48.95 Million |
| 2022 | -429.65% | -67.07% | 0.51x | 12.52x | $-32.58 Million |
| 2023 | 0.00% | -73.21% | 0.63x | 0.00x | $-33.00 Million |
Industry Comparison
This section compares Centogene N.V.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Centogene N.V. (CNTGF) | $-25.28 Million | -33.91% | N/A | $1.47 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |